TK domain mutations are frequently observed in lung adenocarcinoma, a characteristic targeted by TK inhibitors (TKIs) like gefitinib and erlotinib [8], which function by binding to the TK domain and disrupting cell signaling. The gene discussed is TKT; the disease is lung adenocarcinoma.